Atrial FibrillationPhase 3NCT00262600
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate
A Phase 3 study testing warfarin, Dabigatran dose 1 and Dabigatran dose 2 in people with Atrial Fibrillation and Stroke, run by Boehringer Ingelheim at 984 sites in 44 countries.
Trial summary
The primary objective of this trial is to demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Atrial Fibrillation, Stroke
- What is being tested?
- warfarin, Dabigatran dose 1 and Dabigatran dose 2
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 18,113 participants
- Where
- 984 sitesin 44 countries
- Study dates
- Dec 2005to Apr 2009
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
None listed.
Who cannot join
- Prosthetic heart valves requiring anticoagulation per se, or hemodynamically relevant valve disease that is expected to require surgical intervention during the course of the study
- Severe, disabling stroke within the previous 6 months, or any stroke within the previous 14 days
- Conditions associated with an increased risk of bleeding
- Contraindication to warfarin treatment
- Reversible causes of atrial fibrillation (e.g., cardiac surgery, pulmonary embolism, untreated hyperthyroidism).
- Plan to perform a pulmonary vein ablation or surgery for cure of the AF
Show all 15Show fewer
- Severe renal impairment (estimated creatinine clearance <=30 mL/min)
- Active infective endocarditis
- Active liver disease
- Women who are pregnant, lactating, or of childbearing potential who refuse to use a medically acceptable form of contraception throughout the study
- Anaemia (haemoglobin <100g/L) or thrombocytopenia (platelet count <100 x 109/L)
- Patients who have developed transaminase elevations upon exposure to ximelagatran
- Patients who have received an investigational drug in the past 30 days or are participating in another drug study
- Patients considered unreliable by the investigator concerning the requirements for follow-up during the study and/or compliance with study drug administration, has a life expectancy less than the expected duration of the trial due to concomitant disease, or has any condition which in the opinion of the investigator, would not allow safe participation in the study (e.g., drug addiction, alcohol abuse)
- Any known hypersensitivity to galactose if the warfarin used contains galactose.
Trial locations and contacts
984 sites in 44 countries.
910 sites in 44 countries
United States300 sites
1160.26.0203 Boehringer Ingelheim Investigational Site
Akron, Ohio
1160.26.0476 Boehringer Ingelheim Investigational Site
Albany, New York
1160.26.0127 Boehringer Ingelheim Investigational Site
Albuquerque, New Mexico
1160.26.0423 Boehringer Ingelheim Investigational Site
Albuquerque, New Mexico
1160.26.0301 Boehringer Ingelheim Investigational Site
Allentown, Pennsylvania
1160.26.0128 Boehringer Ingelheim Investigational Site
Alliance, Nebraska
1160.26.0454 Boehringer Ingelheim Investigational Site
Altoona, Pennsylvania
1160.26.0388 Boehringer Ingelheim Investigational Site
Anaheim, California
1160.26.0114 Boehringer Ingelheim Investigational Site
Annapolis, Maryland
1160.26.0164 Boehringer Ingelheim Investigational Site
Annapolis, Maryland
1160.26.0195 Boehringer Ingelheim Investigational Site
Arlington, Virginia
1160.26.0353 Boehringer Ingelheim Investigational Site
Asheville, North Carolina
1160.26.0159 Boehringer Ingelheim Investigational Site
Atlanta, Georgia
1160.26.0283 Boehringer Ingelheim Investigational Site
Atlanta, Georgia
1160.26.0338 Boehringer Ingelheim Investigational Site
Atlanta, Georgia
1160.26.0022 Boehringer Ingelheim Investigational Site
Atlantis, Florida
1160.26.0096 Boehringer Ingelheim Investigational Site
Auburn, Maine
1160.26.0021 Boehringer Ingelheim Investigational Site
Augusta, Georgia
1160.26.0319 Boehringer Ingelheim Investigational Site
Augusta, Georgia
1160.26.0419 Boehringer Ingelheim Investigational Site
Aurora, Colorado
1160.26.0129 Boehringer Ingelheim Investigational Site
Austin, Texas
1160.26.0410 Boehringer Ingelheim Investigational Site
Austin, Texas
1160.26.0042 Boehringer Ingelheim Investigational Site
Ayer, Massachusetts
1160.26.0023 Boehringer Ingelheim Investigational Site
Baltimore, Maryland
1160.26.0047 Boehringer Ingelheim Investigational Site
Baltimore, Maryland
1160.26.0079 Boehringer Ingelheim Investigational Site
Baltimore, Maryland
1160.26.0186 Boehringer Ingelheim Investigational Site
Baltimore, Maryland
1160.26.0194 Boehringer Ingelheim Investigational Site
Baltimore, Maryland
1160.26.0155 Boehringer Ingelheim Investigational Site
Bartlesville, Oklahoma
1160.26.0011 Boehringer Ingelheim Investigational Site
Baton Rouge, Louisiana
1160.26.0144 Boehringer Ingelheim Investigational Site
Baton Rouge, Louisiana
1160.26.0404 Boehringer Ingelheim Investigational Site
Baton Rouge, Louisiana
1160.26.0007 Boehringer Ingelheim Investigational Site
Beaufort, South Carolina
1160.26.0255 Boehringer Ingelheim Investigational Site
Bel Air, Maryland
1160.26.0287 Boehringer Ingelheim Investigational Site
Bellevue, Washington
1160.26.0050 Boehringer Ingelheim Investigational Site
Bellingham, Washington
1160.26.0218 Boehringer Ingelheim Investigational Site
Berwyn, Illinois
1160.26.0009 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
1160.26.0046 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
1160.26.0057 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
1160.26.0211 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
1160.26.0141 Boehringer Ingelheim Investigational Site
Bloomfield Hills, Michigan
1160.26.0092 Boehringer Ingelheim Investigational Site
Blue Ridge, Georgia
1160.26.0401 Boehringer Ingelheim Investigational Site
Boston, Massachusetts
1160.26.0077 Boehringer Ingelheim Investigational Site
Bowling Green, Kentucky
1160.26.0382 Boehringer Ingelheim Investigational Site
Boynton Beach, Florida
1160.26.0056 Boehringer Ingelheim Investigational Site
Brandon, Florida
1160.26.0058 Boehringer Ingelheim Investigational Site
Bridgeport, Connecticut
1160.26.0241 Boehringer Ingelheim Investigational Site
Bridgeport, Connecticut
1160.26.0278 Boehringer Ingelheim Investigational Site
Bridgeport, Connecticut
1160.26.0142 Boehringer Ingelheim Investigational Site
Browns Mills, New Jersey
1160.26.0063 Boehringer Ingelheim Investigational Site
Buffalo, New York
1160.26.0040 Boehringer Ingelheim Investigational Site
Burien, Washington
1160.26.0295 Boehringer Ingelheim Investigational Site
Camp Hill, Pennsylvania
1160.26.0434 Boehringer Ingelheim Investigational Site
Canal Fulton, Ohio
1160.26.0441 Boehringer Ingelheim Investigational Site
Carmichael, California
1160.26.0383 Boehringer Ingelheim Investigational Site
Charleston, South Carolina
1160.26.0193 Boehringer Ingelheim Investigational Site
Charleston, West Virginia
1160.26.0080 Boehringer Ingelheim Investigational Site
Charlotte, North Carolina
1160.26.0412 Boehringer Ingelheim Investigational Site
Charlotte, North Carolina
1160.26.0453 Boehringer Ingelheim Investigational Site
Charlottesville, Virginia
1160.26.0084 Boehringer Ingelheim Investigational Site
Chattanooga, Tennessee
1160.26.0125 Boehringer Ingelheim Investigational Site
Cherry Hill, New Jersey
1160.26.0053 Boehringer Ingelheim Investigational Site
Chesapeake, Virginia
1160.26.0184 Boehringer Ingelheim Investigational Site
Chicago, Illinois
1160.26.0233 Boehringer Ingelheim Investigational Site
Chicago, Illinois
1160.26.0324 Boehringer Ingelheim Investigational Site
Chicago, Illinois
1160.26.0457 Boehringer Ingelheim Investigational Site
Chicago, Illinois
1160.26.0083 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio
1160.26.0402 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio
1160.26.0426 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio
1160.26.0479 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio
1160.26.0169 Boehringer Ingelheim Investigational Site
Clarksburg, West Virginia
1160.26.0105 Boehringer Ingelheim Investigational Site
Clearwater, Florida
1160.26.0296 Boehringer Ingelheim Investigational Site
Clearwater, Florida
1160.26.0429 Boehringer Ingelheim Investigational Site
Clearwater, Florida
1160.26.0263 Boehringer Ingelheim Investigational Site
Cleveland, Ohio
1160.26.0480 Boehringer Ingelheim Investigational Site
Cleveland, Ohio
1160.26.0026 Boehringer Ingelheim Investigational Site
Coeur d'Alene, Idaho
1160.26.0321 Boehringer Ingelheim Investigational Site
Colorado Springs, Colorado
1160.26.0449 Boehringer Ingelheim Investigational Site
Colorado Springs, Colorado
1160.26.0398 Boehringer Ingelheim Investigational Site
Columbia, Maryland
1160.26.0055 Boehringer Ingelheim Investigational Site
Columbia, Missouri
1160.26.0172 Boehringer Ingelheim Investigational Site
Columbia, Missouri
1160.26.0267 Boehringer Ingelheim Investigational Site
Columbus, Ohio
1160.26.0161 Boehringer Ingelheim Investigational Site
Conyers, Georgia
1160.26.0044 Boehringer Ingelheim Investigational Site
Cortlandt Manor, New York
1160.26.0139 Boehringer Ingelheim Investigational Site
Corvallis, Oregon
1160.26.0093 Boehringer Ingelheim Investigational Site
Covington, Louisiana
1160.26.0138 Boehringer Ingelheim Investigational Site
Crestview Hills, Kentucky
1160.26.0156 Boehringer Ingelheim Investigational Site
Dallas, Texas
1160.26.0098 Boehringer Ingelheim Investigational Site
Danville, Virginia
1160.26.0035 Boehringer Ingelheim Investigational Site
Dayton, Ohio
1160.26.0376 Boehringer Ingelheim Investigational Site
Daytona Beach, Florida
1160.26.0411 Boehringer Ingelheim Investigational Site
Deerfield Beach, Florida
1160.26.0360 Boehringer Ingelheim Investigational Site
Denver, Colorado
1160.26.0413 Boehringer Ingelheim Investigational Site
Denver, Colorado
1160.26.0225 Boehringer Ingelheim Investigational Site
Detroit, Michigan
1160.26.0268 Boehringer Ingelheim Investigational Site
Dubuque, Iowa
1160.26.0160 Boehringer Ingelheim Investigational Site
East Bridgewater, Massachusetts
1160.26.0072 Boehringer Ingelheim Investigational Site
Elkhorn, Wisconsin
1160.26.0432 Boehringer Ingelheim Investigational Site
Elmer, New Jersey
1160.26.0448 Boehringer Ingelheim Investigational Site
Englewood, New Jersey
1160.26.0325 Boehringer Ingelheim Investigational Site
Eugene, Oregon
1160.26.0237 Boehringer Ingelheim Investigational Site
Evanston, Illinois
1160.26.0041 Boehringer Ingelheim Investigational Site
Evansville, Indiana
1160.26.0085 Boehringer Ingelheim Investigational Site
Fairfield, Connecticut
1160.26.0150 Boehringer Ingelheim Investigational Site
Fairview Park, Ohio
1160.26.0386 Boehringer Ingelheim Investigational Site
Falls Church, Virginia
1160.26.0248 Boehringer Ingelheim Investigational Site
Flemington, New Jersey
1160.26.0373 Boehringer Ingelheim Investigational Site
Flushing, New York
1160.26.0362 Boehringer Ingelheim Investigational Site
Fort Collins, Colorado
1160.26.0074 Boehringer Ingelheim Investigational Site
Fort Myers, Florida
1160.26.0377 Boehringer Ingelheim Investigational Site
Fort Wayne, Indiana
1160.26.0315 Boehringer Ingelheim Investigational Site
Fort Worth, Texas
1160.26.0444 Boehringer Ingelheim Investigational Site
Fort Worth, Texas
1160.26.0428 Boehringer Ingelheim Investigational Site
Fredericksburg, Virginia
1160.26.0145 Boehringer Ingelheim Investigational Site
French Camp, California
1160.26.0333 Boehringer Ingelheim Investigational Site
Fullerton, California
1160.26.0239 Boehringer Ingelheim Investigational Site
Gainesville, Florida
1160.26.0045 Boehringer Ingelheim Investigational Site
Garden City, New York
1160.26.0350 Boehringer Ingelheim Investigational Site
Gastonia, North Carolina
1160.26.0062 Boehringer Ingelheim Investigational Site
Germantown, Tennessee
1160.26.0236 Boehringer Ingelheim Investigational Site
Glenview, Illinois
1160.26.0154 Boehringer Ingelheim Investigational Site
Grand Blanc, Michigan
1160.26.0102 Boehringer Ingelheim Investigational Site
Grand Forks, North Dakota
1160.26.0030 Boehringer Ingelheim Investigational Site
Grand Rapids, Michigan
1160.26.0399 Boehringer Ingelheim Investigational Site
Greeley, Colorado
1160.26.0234 Boehringer Ingelheim Investigational Site
Green Bay, Wisconsin
1160.26.0322 Boehringer Ingelheim Investigational Site
Greensboro, North Carolina
1160.26.0313 Boehringer Ingelheim Investigational Site
Greenville, South Carolina
1160.26.0482 Boehringer Ingelheim Investigational Site
Guilford, Connecticut
1160.26.0086 Boehringer Ingelheim Investigational Site
Gulfport, Mississippi
1160.26.0244 Boehringer Ingelheim Investigational Site
Haddon Heights, New Jersey
1160.26.0311 Boehringer Ingelheim Investigational Site
Harrisonburg, Virginia
1160.26.0443 Boehringer Ingelheim Investigational Site
Haverhill, Massachusetts
1160.26.0452 Boehringer Ingelheim Investigational Site
Haverhill, Massachusetts
1160.26.0346 Boehringer Ingelheim Investigational Site
Henderson, Nevada
1160.26.0294 Boehringer Ingelheim Investigational Site
Hershey, Pennsylvania
1160.26.0173 Boehringer Ingelheim Investigational Site
High Point, North Carolina
1160.26.0078 Boehringer Ingelheim Investigational Site
Hillsboro, Oregon
1160.26.0396 Boehringer Ingelheim Investigational Site
Hines, Illinois
1160.26.0260 Boehringer Ingelheim Investigational Site
Hollywood, Florida
1160.26.0265 Boehringer Ingelheim Investigational Site
Hollywood, Florida
1160.26.0038 Boehringer Ingelheim Investigational Site
Hot Springs, Arkansas
1160.26.0447 Boehringer Ingelheim Investigational Site
Houston, Texas
1160.26.0365 Boehringer Ingelheim Investigational Site
Huntington, West Virginia
1160.26.0206 Boehringer Ingelheim Investigational Site
Huntsville, Alabama
1160.26.0288 Boehringer Ingelheim Investigational Site
Indianapolis, Indiana
1160.26.0352 Boehringer Ingelheim Investigational Site
Indianapolis, Indiana
1160.26.0436 Boehringer Ingelheim Investigational Site
Indianapolis, Indiana
1160.26.0100 Boehringer Ingelheim Investigational Site
Inverness, Florida
1160.26.0033 Boehringer Ingelheim Investigational Site
Jacksonville, Florida
1160.26.0089 Boehringer Ingelheim Investigational Site
Jacksonville, Florida
1160.26.0232 Boehringer Ingelheim Investigational Site
Jacksonville, Florida
1160.26.0240 Boehringer Ingelheim Investigational Site
Jacksonville, Florida
1160.26.0427 Boehringer Ingelheim Investigational Site
Jacksonville, Florida
1160.26.0464 Boehringer Ingelheim Investigational Site
Jacksonville, Florida
1160.26.0209 Boehringer Ingelheim Investigational Site
Jacksonville Beach, Florida
1160.26.0222 Boehringer Ingelheim Investigational Site
Jamestown, North Dakota
1160.26.0028 Boehringer Ingelheim Investigational Site
Jeffersonville, Indiana
1160.26.0369 Boehringer Ingelheim Investigational Site
Jenkintown, Pennsylvania
1160.26.0303 Boehringer Ingelheim Investigational Site
Jersey Shore, Pennsylvania
1160.26.0370 Boehringer Ingelheim Investigational Site
Johnson City, Tennessee
1160.26.0302 Boehringer Ingelheim Investigational Site
Jonesboro, Arkansas
1160.26.0171 Boehringer Ingelheim Investigational Site
Kalamazoo, Michigan
1160.26.0027 Boehringer Ingelheim Investigational Site
Kalispell, Montana
1160.26.0257 Boehringer Ingelheim Investigational Site
Kansas City, Missouri
1160.26.0266 Boehringer Ingelheim Investigational Site
Kansas City, Missouri
1160.26.0201 Boehringer Ingelheim Investigational Site
Kettering, Ohio
1160.26.0483 Boehringer Ingelheim Investigational Site
Killeen, Texas
1160.26.0251 Boehringer Ingelheim Investigational Site
Kingston, New York
1160.26.0384 Boehringer Ingelheim Investigational Site
La Jolla, California
1160.26.0091 Boehringer Ingelheim Investigational Site
La Mesa, California
1160.26.0340 Boehringer Ingelheim Investigational Site
Lacombe, Louisiana
1160.26.0018 Boehringer Ingelheim Investigational Site
Lafayette, Louisiana
1160.26.0391 Boehringer Ingelheim Investigational Site
Lafayette, Louisiana
1160.26.0104 Boehringer Ingelheim Investigational Site
Lake Havasu City, Arizona
1160.26.0012 Boehringer Ingelheim Investigational Site
Lakeland, Florida
1160.26.0246 Boehringer Ingelheim Investigational Site
Lancaster, California
1160.26.0431 Boehringer Ingelheim Investigational Site
Lancaster, Pennsylvania
1160.26.0168 Boehringer Ingelheim Investigational Site
Langhorne, Pennsylvania
1160.26.0205 Boehringer Ingelheim Investigational Site
Lapeer, Michigan
1160.26.0345 Boehringer Ingelheim Investigational Site
Larkspur, California
1160.26.0066 Boehringer Ingelheim Investigational Site
Las Vegas, Nevada
1160.26.0174 Boehringer Ingelheim Investigational Site
Las Vegas, Nevada
1160.26.0430 Boehringer Ingelheim Investigational Site
Las Vegas, Nevada
1160.26.0190 Boehringer Ingelheim Investigational Site
Lebanon, New Hampshire
1160.26.0422 Boehringer Ingelheim Investigational Site
Lexington, Kentucky
1160.26.0108 Boehringer Ingelheim Investigational Site
Lexington, North Carolina
1160.26.0121 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas
1160.26.0191 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas
1160.26.0204 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas
1160.26.0213 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas
1160.26.0455 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas
1160.26.0217 Boehringer Ingelheim Investigational Site
Loma Linda, California
1160.26.0223 Boehringer Ingelheim Investigational Site
Lorain, Ohio
1160.26.0059 Boehringer Ingelheim Investigational Site
Los Angeles, California
1160.26.0088 Boehringer Ingelheim Investigational Site
Los Angeles, California
1160.26.0337 Boehringer Ingelheim Investigational Site
Los Angeles, California
1160.26.0178 Boehringer Ingelheim Investigational Site
Louisville, Kentucky
1160.26.0397 Boehringer Ingelheim Investigational Site
Louisville, Kentucky
1160.26.0335 Boehringer Ingelheim Investigational Site
Lubbock, Texas
1160.26.0214 Boehringer Ingelheim Investigational Site
Lyndhurst, Ohio
1160.26.0099 Boehringer Ingelheim Investigational Site
Madison, Wisconsin
1160.26.0242 Boehringer Ingelheim Investigational Site
Madison, Wisconsin
1160.26.0359 Boehringer Ingelheim Investigational Site
Marshfield, Wisconsin
1160.26.0326 Boehringer Ingelheim Investigational Site
Mather, California
1160.26.0438 Boehringer Ingelheim Investigational Site
Maywood, Illinois
1160.26.0230 Boehringer Ingelheim Investigational Site
McKinney, Texas
1160.26.0293 Boehringer Ingelheim Investigational Site
Meadowbrook, Pennsylvania
1160.26.0259 Boehringer Ingelheim Investigational Site
Melbourne, Florida
1160.26.0358 Boehringer Ingelheim Investigational Site
Melbourne, Florida
1160.26.0331 Boehringer Ingelheim Investigational Site
Melrose Park, Illinois
1160.26.0070 Boehringer Ingelheim Investigational Site
Merced, California
1160.26.0034 Boehringer Ingelheim Investigational Site
Miami, Florida
1160.26.0199 Boehringer Ingelheim Investigational Site
Miami, Florida
1160.26.0461 Boehringer Ingelheim Investigational Site
Milwaukee, Wisconsin
1160.26.0229 Boehringer Ingelheim Investigational Site
Mineola, New York
1160.26.0451 Boehringer Ingelheim Investigational Site
Mineola, New York
1160.26.0131 Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota
1160.26.0421 Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota
1160.26.0115 Boehringer Ingelheim Investigational Site
Mobile, Alabama
1160.26.0252 Boehringer Ingelheim Investigational Site
Morgan City, Louisiana
1160.26.0450 Boehringer Ingelheim Investigational Site
Mt. Pleasant, South Carolina
1160.26.0279 Boehringer Ingelheim Investigational Site
Muskegon, Michigan
1160.26.0323 Boehringer Ingelheim Investigational Site
Nashville, Tennessee
1160.26.0395 Boehringer Ingelheim Investigational Site
Nashville, Tennessee
1160.26.0029 Boehringer Ingelheim Investigational Site
Natick, Massachusetts
1160.26.0243 Boehringer Ingelheim Investigational Site
New Brunswick, New Jersey
1160.26.0090 Boehringer Ingelheim Investigational Site
New Hyde Park, New York
1160.26.0132 Boehringer Ingelheim Investigational Site
New Iberia, Louisiana
1160.26.0299 Tulane University School Of Medicine
New Orleans, Louisiana
1160.26.0183 Boehringer Ingelheim Investigational Site
New Rochelle, New York
1160.26.0316 Boehringer Ingelheim Investigational Site
New York, New York
1160.26.0366 Boehringer Ingelheim Investigational Site
Newark, Delaware
1160.26.0292 Boehringer Ingelheim Investigational Site
Newport News, Virginia
1160.26.0025 Boehringer Ingelheim Investigational Site
Newton, Pennsylvania
1160.26.0446 Boehringer Ingelheim Investigational Site
Newtown, Massachusetts
1160.26.0224 Boehringer Ingelheim Investigational Site
Norfolk, Virginia
1160.26.0364 Boehringer Ingelheim Investigational Site
Normal, Illinois
1160.26.0394 Boehringer Ingelheim Investigational Site
Norristown, Pennsylvania
1160.26.0109 Boehringer Ingelheim Investigational Site
North Chicago, Illinois
1160.26.0003 Boehringer Ingelheim Investigational Site
North Dartmouth, Massachusetts
1160.26.0146 Boehringer Ingelheim Investigational Site
North Massapequa, New York
1160.26.0470 Boehringer Ingelheim Investigational Site
Northborough, Massachusetts
1160.26.0210 Boehringer Ingelheim Investigational Site
Northport, New York
1160.26.0152 Boehringer Ingelheim Investigational Site
Oak Lawn, Illinois
1160.26.0474 Boehringer Ingelheim Investigational Site
Oak Ridge, Tennessee
1160.26.0349 Boehringer Ingelheim Investigational Site
Oakland, California
1160.26.0478 Boehringer Ingelheim Investigational Site
Oakland, New Jersey
1160.26.0392 Boehringer Ingelheim Investigational Site
Ocean City, New Jersey
1160.26.0016 Boehringer Ingelheim Investigational Site
Oceanside, California
1160.26.0298 Boehringer Ingelheim Investigational Site
Olympia, Washington
1160.26.0110 Boehringer Ingelheim Investigational Site
Omaha, Nebraska
1160.26.0227 Boehringer Ingelheim Investigational Site
Orlando, Florida
1160.26.0095 Boehringer Ingelheim Investigational Site
Ormond Beach, Florida
1160.26.0310 Boehringer Ingelheim Investigational Site
Owensboro, Kentucky
1160.26.0087 Boehringer Ingelheim Investigational Site
Palm Springs, California
1160.26.0355 Boehringer Ingelheim Investigational Site
Papillion, Nebraska
1160.26.0459 Boehringer Ingelheim Investigational Site
Pasadena, California
1160.26.0472 Boehringer Ingelheim Investigational Site
Paterson, New Jersey
1160.26.0212 Boehringer Ingelheim Investigational Site
Pawtucket, Rhode Island
1160.26.0037 Boehringer Ingelheim Investigational Site
Pensacola, Florida
1160.26.0076 Boehringer Ingelheim Investigational Site
Pensacola, Florida
1160.26.0081 Boehringer Ingelheim Investigational Site
Pensacola, Florida
1160.26.0111 Boehringer Ingelheim Investigational Site
Pensacola, Florida
1160.26.0304 Boehringer Ingelheim Investigational Site
Peoria, Arizona
1160.26.0445 Boehringer Ingelheim Investigational Site
Petoskey, Michigan
1160.26.0158 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania
1160.26.0181 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania
1160.26.0416 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania
1160.26.0006 Boehringer Ingelheim Investigational Site
Pinehurst, North Carolina
1160.26.0344 Boehringer Ingelheim Investigational Site
Pittsburgh, Pennsylvania
1160.26.0466 Boehringer Ingelheim Investigational Site
Pittsburgh, Pennsylvania
1160.26.0467 Boehringer Ingelheim Investigational Site
Plano, Texas
1160.26.0137 Boehringer Ingelheim Investigational Site
Port Charlotte, Florida
1160.26.0389 Boehringer Ingelheim Investigational Site
Port Charlotte, Florida
1160.26.0417 Boehringer Ingelheim Investigational Site
Port Charlotte, Florida
1160.26.0245 Boehringer Ingelheim Investigational Site
Portland, Oregon
1160.26.0075 Boehringer Ingelheim Investigational Site
Poughkeepsie, New York
1160.26.0348 Boehringer Ingelheim Investigational Site
Rapid City, South Dakota
1160.26.0216 Boehringer Ingelheim Investigational Site
Redondo Beach, California
1160.26.0135 Boehringer Ingelheim Investigational Site
Riverside, California
1160.26.0202 Boehringer Ingelheim Investigational Site
Robbinsdale, Minnesota
1160.26.0197 Boehringer Ingelheim Investigational Site
Rochester, New York
1160.26.0320 Boehringer Ingelheim Investigational Site
Rochester, New York
1160.26.0274 Boehringer Ingelheim Investigational Site
Rochester Hills, Michigan
1160.26.0198 Boehringer Ingelheim Investigational Site
Rockford, Illinois
1160.26.0332 Boehringer Ingelheim Investigational Site
Rockledge, Florida
1160.26.0177 Boehringer Ingelheim Investigational Site
Rockville, Maryland
1160.26.0162 Boehringer Ingelheim Investigational Site
Sacramento, California
1160.26.0300 Boehringer Ingelheim Investigational Site
Sacramento, California
1160.26.0371 Boehringer Ingelheim Investigational Site
Sacramento, California
1160.26.0226 Boehringer Ingelheim Investigational Site
Safety Harbor, Florida
1160.26.0165 Boehringer Ingelheim Investigational Site
Saginaw, Michigan
1160.26.0336 Boehringer Ingelheim Investigational Site
Saint Charles, Missouri
1160.26.0101 Boehringer Ingelheim Investigational Site
Saint Paul, Minnesota
1160.26.0220 Boehringer Ingelheim Investigational Site
Salem, Virginia
1160.26.0073 Boehringer Ingelheim Investigational Site
Salisbury, Maryland
Canada54 sites
1160.26.0679 Boehringer Ingelheim Investigational Site
Ajax, Ontario
1160.26.0676 Boehringer Ingelheim Investigational Site
Antigonish Nova Scotia, Nova Scotia
1160.26.0707 Boehringer Ingelheim Investigational Site
Bay Roberts, Newfoundland and Labrador
1160.26.0677 Boehringer Ingelheim Investigational Site
Brampton, Ontario
1160.26.0674 Boehringer Ingelheim Investigational Site
Burlington, Ontario
1160.26.0694 Boehringer Ingelheim Investigational Site
Calgary, Alberta
1160.26.0696 Boehringer Ingelheim Investigational Site
Calgary, Alberta
1160.26.0702 Boehringer Ingelheim Investigational Site
Cambridge, Ontario
1160.26.0720 Boehringer Ingelheim Investigational Site
Cambridge, Ontario
1160.26.0680 Boehringer Ingelheim Investigational Site
Coquitlam, British Columbia
1160.26.0712 Boehringer Ingelheim Investigational Site
Coquitlam, British Columbia
1160.26.0671 Clinical Research & Diagnostic Solutions Inc.
Etobicoke, Ontario
1160.26.0715 Boehringer Ingelheim Investigational Site
Greater Sudbury, Ontario
1160.26.0692 Boehringer Ingelheim Investigational Site
Grimsby, Ontario
1160.26.0703 Boehringer Ingelheim Investigational Site
Halifax, Nova Scotia
1160.26.0685 Boehringer Ingelheim Investigational Site
Hamilton, Ontario
1160.26.0697 Boehringer Ingelheim Investigational Site
Hamilton, Ontario
1160.26.0710 Boehringer Ingelheim Investigational Site
Hamilton, Ontario
1160.26.0719 Boehringer Ingelheim Investigational Site
Hamilton, Ontario
1160.26.0721 Boehringer Ingelheim Investigational Site
Hamilton, Ontario
1160.26.0706 Boehringer Ingelheim Investigational Site
Kelowna, British Columbia
1160.26.0689 Boehringer Ingelheim Investigational Site
Kitchener, Ontario
1160.26.0693 Boehringer Ingelheim Investigational Site
Longueuil, Quebec
1160.26.0695 Boehringer Ingelheim Investigational Site
Mississauga, Ontario
1160.26.0708 Boehringer Ingelheim Investigational Site
Mississauga, Ontario
1160.26.0724 Boehringer Ingelheim Investigational Site
Mississauga, Ontario
1160.26.0681 Boehringer Ingelheim Investigational Site
Montreal, Quebec
1160.26.0683 Boehringer Ingelheim Investigational Site
Montreal, Quebec
1160.26.0705 Boehringer Ingelheim Investigational Site
Montreal, Quebec
1160.26.0709 Boehringer Ingelheim Investigational Site
Montreal, Quebec
1160.26.0716 Boehringer Ingelheim Investigational Site
Montreal, Quebec
1160.26.0725 Boehringer Ingelheim Investigational Site
Nanaimo, British Columbia
1160.26.0691 Boehringer Ingelheim Investigational Site
New Westminster, British Columbia
1160.26.0688 Boehringer Ingelheim Investigational Site
Newmarket, Ontario
1160.26.0672 Boehringer Ingelheim Investigational Site
Oshawa, Ontario
1160.26.0687 Boehringer Ingelheim Investigational Site
Ottawa, Ontario
1160.26.0701 Boehringer Ingelheim Investigational Site
Portage la Prairie, Manitoba
1160.26.0717 Boehringer Ingelheim Investigational Site
Québec, Quebec
1160.26.0713 Boehringer Ingelheim Investigational Site
Saint George-de-Beauce, Quebec
1160.26.0699 Boehringer Ingelheim Investigational Site
Saint-Charles-Borromée, Quebec
1160.26.0675 Boehringer Ingelheim Investigational Site
Saint-Hyacinthe, Quebec
1160.26.0704 Boehringer Ingelheim Investigational Site
Saint-Jérôme, Quebec
1160.26.0673 Boehringer Ingelheim Investigational Site
Saskatoon, Saskatchewan
1160.26.0678 Boehringer Ingelheim Investigational Site
Saskatoon, Saskatchewan
1160.26.0723 Boehringer Ingelheim Investigational Site
Scarborough Village, Ontario
1160.26.0700 Boehringer Ingelheim Investigational Site
Ste-Foy, Quebec
1160.26.0682 Boehringer Ingelheim Investigational Site
Terrebonne (Lachenaie), Quebec
1160.26.0690 Boehringer Ingelheim Investigational Site
Thunder Bay, Ontario
1160.26.0684 Boehringer Ingelheim Investigational Site
Toronto, Ontario
1160.26.0718 Boehringer Ingelheim Investigational Site
Toronto, Ontario
1160.26.0714 Boehringer Ingelheim Investigational Site
Victoria, British Columbia
1160.26.0711 Boehringer Ingelheim Investigational Site
Waterloo, Ontario
1160.26.0686 Boehringer Ingelheim Investigational Site
Windsor, Ontario
1160.26.0698 Boehringer Ingelheim Investigational Site
Winnipeg, Manitoba
Japan49 sites
1160.26.1204 Boehringer Ingelheim Investigational Site
Abeno-ku, Osaka, Osaka
1160.26.1209 Boehringer Ingelheim Investigational Site
Aki-gun, Hiroshima
1160.26.1193 Boehringer Ingelheim Investigational Site
Aoba-ku, Sendai, Miyagi
1160.26.1211 Boehringer Ingelheim Investigational Site
Chuo-ku, Fukuoka, Fukuoka
1160.26.1225 Boehringer Ingelheim Investigational Site
Chuo-ku, Fukuoka, Fukuoka
1160.26.1221 Boehringer Ingelheim Investigational Site
Chuo-ku, Kobe, Hyogo
1160.26.1219 Boehringer Ingelheim Investigational Site
Chuo-ku, Osaka, Osaka
1160.26.1229 Boehringer Ingelheim Investigational Site
Fujioka-shi , Gunma-ken
1160.26.1232 Boehringer Ingelheim Investigational Site
Fukushima-shi,Fukushima-ken
1160.26.1228 Boehringer Ingelheim Investigational Site
Higashimatsushimashi, Miyagi-ken
1160.26.1208 Boehringer Ingelheim Investigational Site
Himeji, Hyogo
1160.26.1214 Boehringer Ingelheim Investigational Site
Iida, Nagano
1160.26.1240 Boehringer Ingelheim Investigational Site
Isesaki-shi,Gunma
1160.26.1224 Boehringer Ingelheim Investigational Site
Iwakuni, Yamaguchi
1160.26.1194 Boehringer Ingelheim Investigational Site
Izumi-ku, Sendai, Miyagi
1160.26.1241 Boehringer Ingelheim Investigational Site
Kamigyo-ku, Kyoto
1160.26.1220 Boehringer Ingelheim Investigational Site
Kawachinagano, Osaka
1160.26.1203 Boehringer Ingelheim Investigational Site
Kita-ku, Osaka, Osaka
1160.26.1207 Boehringer Ingelheim Investigational Site
Kita-ku, Sakai, Osaka
1160.26.1231 Boehringer Ingelheim Investigational Site
Komatsu-shi,Ishikawa -ken
1160.26.1233 Boehringer Ingelheim Investigational Site
Kyoto-shi,Kyoto
1160.26.1242 Boehringer Ingelheim Investigational Site
Matsumoto, Nagano
1160.26.1210 Boehringer Ingelheim Investigational Site
Minami-ku, Fukuoka, Fukuoka
1160.26.1200 Boehringer Ingelheim Investigational Site
Minato-ku, Nagoya, Aichi
1160.26.1201 Boehringer Ingelheim Investigational Site
Minato-ku, Nagoya, Aichi
1160.26.1218 Boehringer Ingelheim Investigational Site
Minato, Tokyo
1160.26.1216 Boehringer Ingelheim Investigational Site
Narashino, Chiba
1160.26.1237 Boehringer Ingelheim Investigational Site
Nishinomiya-shi,Hyogo
1160.26.1223 Boehringer Ingelheim Investigational Site
Okayama, Okayama
1160.26.1197 Boehringer Ingelheim Investigational Site
Oota, Tokyo
1160.26.1212 Boehringer Ingelheim Investigational Site
Otaru, Hokkaido
1160.26.1230 Boehringer Ingelheim Investigational Site
Sagamihara, Kanagawa-ken
1160.26.1238 Boehringer Ingelheim Investigational Site
Sapporo-shi,Hokkai-do
1160.26.1217 Boehringer Ingelheim Investigational Site
Shibuya, Tokyo
1160.26.1196 Boehringer Ingelheim Investigational Site
Shinjuku, Tokyo
1160.26.1191 Boehringer Ingelheim Investigational Site
Shiroishi-ku, Sapporo, Hokkaido
1160.26.1192 Boehringer Ingelheim Investigational Site
Shiroishi-ku, Sapporo, Hokkaido
1160.26.1235 Boehringer Ingelheim Investigational Site
Suita-shi, Osaka
1160.26.1236 Boehringer Ingelheim Investigational Site
Suita-shi, Osaka
1160.26.1206 Boehringer Ingelheim Investigational Site
Suita, Osaka
1160.26.1205 Boehringer Ingelheim Investigational Site
Sumiyoshi-ku, Osaka, Osaka
1160.26.1234 Boehringer Ingelheim Investigational Site
Takatsuki-shi,Osaka
1160.26.1215 Boehringer Ingelheim Investigational Site
Tokorozawa, Saitama
1160.26.1198 Boehringer Ingelheim Investigational Site
Totsuka-ku, Yokohama, Kanagawa
1160.26.1195 Boehringer Ingelheim Investigational Site
Tsuchiura, Ibaragi
1160.26.1199 Boehringer Ingelheim Investigational Site
Ueda, Nagano
1160.26.1222 Boehringer Ingelheim Investigational Site
Wakayama, Wakayama
1160.26.1227 Boehringer Ingelheim Investigational Site
Yanagawa, Fukuoka
1160.26.1243 Boehringer Ingelheim Investigational Site
Yao, Osaka
France41 sites
1160.26.0875A Boehringer Ingelheim Investigational Site
Abbeville
1160.26.0882A Boehringer Ingelheim Investigational Site
Angers
1160.26.0882B Boehringer Ingelheim Investigational Site
Angers
1160.26.0882C Boehringer Ingelheim Investigational Site
Angers
1160.26.0882D Boehringer Ingelheim Investigational Site
Angers
1160.26.0882E Boehringer Ingelheim Investigational Site
Angers
1160.26.0882G Boehringer Ingelheim Investigational Site
Angers
1160.26.0882H Boehringer Ingelheim Investigational Site
Angers
1160.26.0882I Boehringer Ingelheim Investigational Site
Angers
1160.26.0882K Boehringer Ingelheim Investigational Site
Angers
1160.26.0882L Boehringer Ingelheim Investigational Site
Angers
1160.26.0884A Boehringer Ingelheim Investigational Site
Angers
1160.26.0887A Boehringer Ingelheim Investigational Site
Cholet
1160.26.0889A Boehringer Ingelheim Investigational Site
Gap
1160.26.0888A Boehringer Ingelheim Investigational Site
Grenoble
1160.26.0880B Boehringer Ingelheim Investigational Site
Joué Les Tours
1160.26.0880C Boehringer Ingelheim Investigational Site
Joué Les Tours
1160.26.0880D Boehringer Ingelheim Investigational Site
Joué Les Tours
1160.26.0880E Boehringer Ingelheim Investigational Site
Joué Les Tours
1160.26.0879A Boehringer Ingelheim Investigational Site
Joué-lès-Tours
1160.26.0879B Boehringer Ingelheim Investigational Site
Joué-lès-Tours
1160.26.0879C Boehringer Ingelheim Investigational Site
Joué-lès-Tours
1160.26.0879E Boehringer Ingelheim Investigational Site
Joué-lès-Tours
1160.26.0879F Boehringer Ingelheim Investigational Site
Joué-lès-Tours
1160.26.0879G Boehringer Ingelheim Investigational Site
Joué-lès-Tours
1160.26.0879H Boehringer Ingelheim Investigational Site
Joué-lès-Tours
1160.26.0879S Boehringer Ingelheim Investigational Site
Joué-lès-Tours
1160.26.0880A Boehringer Ingelheim Investigational Site
Joué-lès-Tours
1160.26.0880F Boehringer Ingelheim Investigational Site
Joué-lès-Tours
1160.26.0880G Boehringer Ingelheim Investigational Site
Joué-lès-Tours
1160.26.0880J Boehringer Ingelheim Investigational Site
Joué-lès-Tours
1160.26.0881A Boehringer Ingelheim Investigational Site
Joué-lès-Tours
1160.26.0881D Boehringer Ingelheim Investigational Site
Joué-lès-Tours
1160.26.0874A Boehringer Ingelheim Investigational Site
Langres
1160.26.0874B Boehringer Ingelheim Investigational Site
Langres
1160.26.0871A Boehringer Ingelheim Investigational Site
Paris
1160.26.0873A Boehringer Ingelheim Investigational Site
Toulouse
1160.26.0886A Boehringer Ingelheim Investigational Site
Tourcoing
1160.26.0872A Boehringer Ingelheim Investigational Site
Valenciennes
1160.26.0872B Boehringer Ingelheim Investigational Site
Valenciennes
1160.26.0872C Boehringer Ingelheim Investigational Site
Valenciennes
Israel32 sites
1160.26.1110 Boehringer Ingelheim Investigational Site
Afula
1160.26.1121 Boehringer Ingelheim Investigational Site
Afula
1160.26.1111 Boehringer Ingelheim Investigational Site
Ashkelon
1160.26.1102 Boehringer Ingelheim Investigational Site
Beersheba
1160.26.1117 Boehringer Ingelheim Investigational Site
Giv‘atayim
1160.26.1112 Boehringer Ingelheim Investigational Site
Hadera
1160.26.1091 Boehringer Ingelheim Investigational Site
Haifa
1160.26.1113 Boehringer Ingelheim Investigational Site
Haifa
1160.26.1114 Boehringer Ingelheim Investigational Site
Haifa
1160.26.1116 Boehringer Ingelheim Investigational Site
Haifa
1160.26.1118 Boehringer Ingelheim Investigational Site
Haifa
1160.26.1105 Boehringer Ingelheim Investigational Site
Holon
1160.26.1097 Boehringer Ingelheim Investigational Site
Jerusalem
1160.26.1101 Boehringer Ingelheim Investigational Site
Jerusalem
1160.26.1104 Boehringer Ingelheim Investigational Site
Jerusalem
1160.26.1106 Boehringer Ingelheim Investigational Site
Jerusalem
1160.26.1119 Boehringer Ingelheim Investigational Site
Kfar Saba
1160.26.1115 Boehringer Ingelheim Investigational Site
Nazareth
1160.26.1096 Boehringer Ingelheim Investigational Site
Petah Tikva
1160.26.1093 Boehringer Ingelheim Investigational Site
Ramat Gan
1160.26.1094 Boehringer Ingelheim Investigational Site
Ramat Gan
1160.26.1095 Boehringer Ingelheim Investigational Site
Ramat Gan
1160.26.1100 Boehringer Ingelheim Investigational Site
Rehovot
1160.26.1103 Boehringer Ingelheim Investigational Site
Safed
1160.26.1107 Boehringer Ingelheim Investigational Site
Tel Aviv
1160.26.1108 Boehringer Ingelheim Investigational Site
Tel Aviv
1160.26.1109 Boehringer Ingelheim Investigational Site
Tel Aviv
1160.26.1120 Boehringer Ingelheim Investigational Site
Tel Aviv
1160.26.1122 Boehringer Ingelheim Investigational Site
Tel Aviv
1160.26.1092 Boehringer Ingelheim Investigational Site
Tel HaShomer
1160.26.1098 Boehringer Ingelheim Investigational Site
Tel HaShomer
1160.26.1099 Boehringer Ingelheim Investigational Site
Tsrifin
Netherlands31 sites
1160.26.1337 Boehringer Ingelheim Investigational Site
's-Hertogenbosch
1160.26.1344 Boehringer Ingelheim Investigational Site
Almelo
1160.26.1331 Boehringer Ingelheim Investigational Site
Amsterdam
1160.26.1336 Boehringer Ingelheim Investigational Site
Apeldoorn
1160.26.1332 Boehringer Ingelheim Investigational Site
Breda
1160.26.1349 Boehringer Ingelheim Investigational Site
Den Helder
1160.26.1345 Boehringer Ingelheim Investigational Site
Deventer
1160.26.1360 Boehringer Ingelheim Investigational Site
Dirksland
1160.26.1348 Boehringer Ingelheim Investigational Site
Dordrecht
1160.26.1340 Boehringer Ingelheim Investigational Site
Ede
1160.26.1358 Boehringer Ingelheim Investigational Site
Eindhoven
1160.26.1338 Boehringer Ingelheim Investigational Site
Enschede
1160.26.1343 Boehringer Ingelheim Investigational Site
Goes
1160.26.1347 Boehringer Ingelheim Investigational Site
Gorinchem
1160.26.1333 Boehringer Ingelheim Investigational Site
Groningen
1160.26.1355 Boehringer Ingelheim Investigational Site
Groningen
1160.26.1361 Boehringer Ingelheim Investigational Site
Heerlen
1160.26.1339 Boehringer Ingelheim Investigational Site
Hengelo
1160.26.1346 Boehringer Ingelheim Investigational Site
Hilversum
1160.26.1356 Boehringer Ingelheim Investigational Site
Hoorn
1160.26.1359 Boehringer Ingelheim Investigational Site
Maastricht
1160.26.1341 Boehringer Ingelheim Investigational Site
Meppel
1160.26.1354 Boehringer Ingelheim Investigational Site
Rotterdam
1160.26.1351 Boehringer Ingelheim Investigational Site
Sneek
1160.26.1334 Boehringer Ingelheim Investigational Site
Spiijkenisse
1160.26.1335 Boehringer Ingelheim Investigational Site
Terneuzen
1160.26.1353 Boehringer Ingelheim Investigational Site
Tiel
1160.26.1352 Boehringer Ingelheim Investigational Site
Tilburg
1160.26.1350 Boehringer Ingelheim Investigational Site
Veldhoven
1160.26.1342 Boehringer Ingelheim Investigational Site
Velp
1160.26.1357 Boehringer Ingelheim Investigational Site
Venlo
Germany27 sites
1160.26.0932 Boehringer Ingelheim Investigational Site
Berlin
1160.26.0948 Boehringer Ingelheim Investigational Site
Berlin
1160.26.0962 Boehringer Ingelheim Investigational Site
Berlin
1160.26.0940 Boehringer Ingelheim Investigational Site
Bochum
1160.26.0936 Boehringer Ingelheim Investigational Site
Coburg
1160.26.0963 Boehringer Ingelheim Investigational Site
Cologne
1160.26.0968 Boehringer Ingelheim Investigational Site
Dachau
1160.26.0972 Boehringer Ingelheim Investigational Site
Dortmund
1160.26.0957 Boehringer Ingelheim Investigational Site
Duisburg
1160.26.0971 Boehringer Ingelheim Investigational Site
Erlangen
1160.26.0965 Boehringer Ingelheim Investigational Site
Eschweiler
1160.26.0934 Boehringer Ingelheim Investigational Site
Essen
1160.26.0931 Boehringer Ingelheim Investigational Site
Frankfurt am Main
1160.26.0943 Boehringer Ingelheim Investigational Site
Heidelberg
1160.26.0955 Boehringer Ingelheim Investigational Site
Kassel
1160.26.0946 Boehringer Ingelheim Investigational Site
Lahr
1160.26.0944 Boehringer Ingelheim Investigational Site
Limburg
1160.26.0951 Boehringer Ingelheim Investigational Site
Mainz
1160.26.0933 Boehringer Ingelheim Investigational Site
Mannheim
1160.26.0945 Boehringer Ingelheim Investigational Site
Mannheim
1160.26.0970 Boehringer Ingelheim Investigational Site
Mannheim
1160.26.0947 Boehringer Ingelheim Investigational Site
München
1160.26.0952 Boehringer Ingelheim Investigational Site
München
1160.26.0941 Boehringer Ingelheim Investigational Site
Papenburg
1160.26.0959 Boehringer Ingelheim Investigational Site
Suhl
1160.26.0937 Boehringer Ingelheim Investigational Site
Witten
1160.26.0966 Boehringer Ingelheim Investigational Site
Wuppertal
Belgium25 sites
1160.26.0564 Boehringer Ingelheim Investigational Site
Aalst
1160.26.0573 Boehringer Ingelheim Investigational Site
Antwerp
1160.26.0575 Boehringer Ingelheim Investigational Site
Antwerp
1160.26.0572 Boehringer Ingelheim Investigational Site
Brasschaat
1160.26.0577 Boehringer Ingelheim Investigational Site
Bruges
1160.26.0571 Boehringer Ingelheim Investigational Site
Brussels
1160.26.0581 Boehringer Ingelheim Investigational Site
Brussels
1160.26.0585 Boehringer Ingelheim Investigational Site
Brussels
1160.26.0586 Boehringer Ingelheim Investigational Site
Brussels
1160.26.0563 Boehringer Ingelheim Investigational Site
Edegem
1160.26.0578 Boehringer Ingelheim Investigational Site
Genk
1160.26.0587 Boehringer Ingelheim Investigational Site
Genk
1160.26.0574 Boehringer Ingelheim Investigational Site
Ghent
1160.26.0588 Boehringer Ingelheim Investigational Site
Gilly
1160.26.0580 Boehringer Ingelheim Investigational Site
Haine-St.-Paul
1160.26.0568 Boehringer Ingelheim Investigational Site
Hasselt
1160.26.0569 Boehringer Ingelheim Investigational Site
Kortrijk
1160.26.0561 Boehringer Ingelheim Investigational Site
Leuven
1160.26.0579 Boehringer Ingelheim Investigational Site
Liège
1160.26.0583 Boehringer Ingelheim Investigational Site
Liège
1160.26.0589 Boehringer Ingelheim Investigational Site
Mol
1160.26.0567 Boehringer Ingelheim Investigational Site
Ostend
1160.26.0570 Boehringer Ingelheim Investigational Site
Roeselare
1160.26.0566 Boehringer Ingelheim Investigational Site
Tienen
1160.26.0562 Boehringer Ingelheim Investigational Site
Turnhout
India20 sites
1160.26.1056 Boehringer Ingelheim Investigational Site
Ahmedabad
1160.26.1057 Boehringer Ingelheim Investigational Site
Ahmedabad
1160.26.1064 Boehringer Ingelheim Investigational Site
Bangalore
1160.26.1065 Boehringer Ingelheim Investigational Site
Bangalore
1160.26.1071 Boehringer Ingelheim Investigational Site
Bikaner
1160.26.1066 Boehringer Ingelheim Investigational Site
Chennai
1160.26.1069 Boehringer Ingelheim Investigational Site
Coimbatore
1160.26.1062 Boehringer Ingelheim Investigational Site
Hyderabad
1160.26.1058 Boehringer Ingelheim Investigational Site
Indore
1160.26.1053 Boehringer Ingelheim Investigational Site
Jaipur
1160.26.1073 Boehringer Ingelheim Investigational Site
Jaipur
1160.26.1067 Boehringer Ingelheim Investigational Site
Kerala
1160.26.1068 Boehringer Ingelheim Investigational Site
Kottayam
1160.26.1055 Boehringer Ingelheim Investigational Site
Lucknow
1160.26.1051 Boehringer Ingelheim Investigational Site
Ludhiana
1160.26.1060 Boehringer Ingelheim Investigational Site
Mumbai
1160.26.1072 Boehringer Ingelheim Investigational Site
Mysore
1160.26.1059 Boehringer Ingelheim Investigational Site
Nagpur
1160.26.1052 Boehringer Ingelheim Investigational Site
New Delhi
1160.26.1070 Boehringer Ingelheim Investigational Site
Pune
Italy18 sites
1160.26.1169 Boehringer Ingelheim Investigational Site
Arezzo
1160.26.1172 Boehringer Ingelheim Investigational Site
Ascoli Piceno
1160.26.1180 Boehringer Ingelheim Investigational Site
Bentivoglio (BO)
1160.26.1161 Boehringer Ingelheim Investigational Site
Bologna
1160.26.1163 Boehringer Ingelheim Investigational Site
Castelnuovo Garfagnana
1160.26.1178 Boehringer Ingelheim Investigational Site
Chieti
1160.26.1171 Boehringer Ingelheim Investigational Site
Colleferro
1160.26.1174 Boehringer Ingelheim Investigational Site
Cremona
1160.26.1167 Boehringer Ingelheim Investigational Site
Eboli
1160.26.1168 Boehringer Ingelheim Investigational Site
Isernia
1160.26.1162 Boehringer Ingelheim Investigational Site
Legnago
1160.26.1177 Boehringer Ingelheim Investigational Site
Mantua
1160.26.1165 Boehringer Ingelheim Investigational Site
Perugia SAN Sisto
1160.26.1175 Boehringer Ingelheim Investigational Site
Roma
1160.26.1181 Boehringer Ingelheim Investigational Site
San Bonifacio
1160.26.1173 Boehringer Ingelheim Investigational Site
San Daniele del Friuli
1160.26.1170 Boehringer Ingelheim Investigational Site
Sassari
1160.26.1176 Boehringer Ingelheim Investigational Site
Sassari
United Kingdom16 sites
1160.26.1744 Boehringer Ingelheim Investigational Site
Birmingham
1160.26.1746 Boehringer Ingelheim Investigational Site
Chertsey
1160.26.1747 Boehringer Ingelheim Investigational Site
Glasgow
1160.26.1750 Boehringer Ingelheim Investigational Site
Harrow
1160.26.1753 Boehringer Ingelheim Investigational Site
Hull
1160.26.1755 Boehringer Ingelheim Investigational Site
Kirkcaldy, Fife
1160.26.1741 Boehringer Ingelheim Investigational Site
London
1160.26.1756 Boehringer Ingelheim Investigational Site
London
1160.26.1749 Boehringer Ingelheim Investigational Site
Londonderry
1160.26.1742 Boehringer Ingelheim Investigational Site
Newcastle upon Tyne
1160.26.1751 Boehringer Ingelheim Investigational Site
Newport
1160.26.1752 Boehringer Ingelheim Investigational Site
Northampton
1160.26.1745 Boehringer Ingelheim Investigational Site
Portadown, County Atrim
1160.26.1743 Boehringer Ingelheim Investigational Site
Romford, Essex
1160.26.1754 Boehringer Ingelheim Investigational Site
Stoke-on-Trent
1160.26.1748 Boehringer Ingelheim Investigational Site
York
Bulgaria15 sites
1160.26.0620 Boehringer Ingelheim Investigational Site
Pleven
1160.26.0611 Boehringer Ingelheim Investigational Site
Sofia
1160.26.0612 Boehringer Ingelheim Investigational Site
Sofia
1160.26.0613 Boehringer Ingelheim Investigational Site
Sofia
1160.26.0614 Boehringer Ingelheim Investigational Site
Sofia
1160.26.0615 Boehringer Ingelheim Investigational Site
Sofia
1160.26.0616 Boehringer Ingelheim Investigational Site
Sofia
1160.26.0617 Boehringer Ingelheim Investigational Site
Sofia
1160.26.0618 Boehringer Ingelheim Investigational Site
Sofia
1160.26.0622 Boehringer Ingelheim Investigational Site
Sofia
1160.26.0623 Boehringer Ingelheim Investigational Site
Sofia
1160.26.0624 Boehringer Ingelheim Investigational Site
Sofia
1160.26.0625 Boehringer Ingelheim Investigational Site
Sofia
1160.26.0626 Boehringer Ingelheim Investigational Site
Stara Zagora
1160.26.0621 Boehringer Ingelheim Investigational Site
Varna
Russia15 sites
1160.26.1501 Boehringer Ingelheim Investigational Site
Moscow
1160.26.1502 Boehringer Ingelheim Investigational Site
Moscow
1160.26.1503 Boehringer Ingelheim Investigational Site
Moscow
1160.26.1504 Boehringer Ingelheim Investigational Site
Moscow
1160.26.1505 Boehringer Ingelheim Investigational Site
Moscow
1160.26.1506 Boehringer Ingelheim Investigational Site
Moscow
1160.26.1507 Boehringer Ingelheim Investigational Site
Moscow
1160.26.1508 Boehringer Ingelheim Investigational Site
Moscow
1160.26.1509 Boehringer Ingelheim Investigational Site
Moscow
1160.26.1510 Boehringer Ingelheim Investigational Site
Moscow
1160.26.1511 Boehringer Ingelheim Investigational Site
Moscow
1160.26.1512 Boehringer Ingelheim Investigational Site
Saint Petersburg
1160.26.1513 Boehringer Ingelheim Investigational Site
Saint Petersburg
1160.26.1514 Boehringer Ingelheim Investigational Site
Saint Petersburg
1160.26.1515 Boehringer Ingelheim Investigational Site
Saint Petersburg
Brazil14 sites
1160.26.550648 Boehringer Ingelheim Investigational Site
Belo Horizonte
1160.26.550654 Boehringer Ingelheim Investigational Site
Blumenau
1160.26.550644 Boehringer Ingelheim Investigational Site
Campinas
1160.26.550650 Boehringer Ingelheim Investigational Site
Curitiba
1160.26.550651 Boehringer Ingelheim Investigational Site
Curitiba
1160.26.550653 Boehringer Ingelheim Investigational Site
Curitiba
1160.26.550652 Boehringer Ingelheim Investigational Site
Goiânia
1160.26.550645 Boehringer Ingelheim Investigational Site
Marília
1160.26.550646 Boehringer Ingelheim Investigational Site
São José do Rio Preto
1160.26.550647 Boehringer Ingelheim Investigational Site
São José do Rio Preto
1160.26.550641 Boehringer Ingelheim Investigational Site
São Paulo
1160.26.550642 Boehringer Ingelheim Investigational Site
São Paulo
1160.26.550643 Boehringer Ingelheim Investigational Site
São Paulo
1160.26.550649 Boehringer Ingelheim Investigational Site
Uberaba
Sweden14 sites
1160.26.1633 Sahlgrenska Sjukhuset
Göteboerg
1160.26.1629 AVK-mott, Spec.M1, Länssjukhuset Ryhov
Jönköping
1160.26.1631 Universitetssjukhuset i Linköping
Linköping
1160.26.1627 Hjärtmott. ING 35, Malmö Universitetssjukhus MAS
Malmö
1160.26.1628 Rådhusg. 29, Lars Mörlids Läkarmottagning
Nässjö
1160.26.1625 Hjärtmott./Medicinkliniken, Vrinnevisjukhuset
Norrköping
1160.26.1623 Kardiologiska kliniken, Universitetssjukhuset
Örebro
1160.26.1626 Hjärtkärllaboratoriet, Danderyds Sjukhus AB
Stockholm
1160.26.1632 Capio S:t Görans Sjukhus
Stockholm
1160.26.1634 Södersjukhuset
Stockholm
1160.26.1624 Klin. forskningscentrum, Norrlands Universitetssjukhus
Umeå
1160.26.1621 Kardiologiska kliniken, Akademiska Sjukhuset
Uppsala
1160.26.1635 UCR/Uppsala
Uppsala
1160.26.1622 Hjärtmottagningen, Centrallasarettet
Västerås
Argentina13 sites
1160.26.0523 Boehringer Ingelheim Investigational Site
Bahía Blanca
1160.26.0524 Boehringer Ingelheim Investigational Site
Capital Federal
1160.26.0533 Boehringer Ingelheim Investigational Site
Capital Federal
1160.26.0526 Boehringer Ingelheim Investigational Site
Cipolletti
1160.26.0531 Boehringer Ingelheim Investigational Site
Córdoba
1160.26.0529 Boehringer Ingelheim Investigational Site
Coronel Suárez
1160.26.0530 Boehringer Ingelheim Investigational Site
La Plata
1160.26.0527 Boehringer Ingelheim Investigational Site
Mar del Plata
1160.26.0532 Boehringer Ingelheim Investigational Site
Mar del Plata
1160.26.0525 Boehringer Ingelheim Investigational Site
Quilmes
1160.26.0521 Boehringer Ingelheim Investigational Site
Rosario
1160.26.0528 Boehringer Ingelheim Investigational Site
Salta
1160.26.0522 Boehringer Ingelheim Investigational Site
Santa Fe
China13 sites
1160.26.0771 Boehringer Ingelheim Investigational Site
Beijing
1160.26.0772 Boehringer Ingelheim Investigational Site
Beijing
1160.26.0773 Boehringer Ingelheim Investigational Site
Beijing
1160.26.0774 Boehringer Ingelheim Investigational Site
Beijing
1160.26.0775 Boehringer Ingelheim Investigational Site
Beijing
1160.26.0783 Boehringer Ingelheim Investigational Site
Beijing
1160.26.0784 Boehringer Ingelheim Investigational Site
Hangzhou
1160.26.0776 Boehringer Ingelheim Investigational Site
Harbin
1160.26.0778 Boehringer Ingelheim Investigational Site
Qingdao
1160.26.0781 Boehringer Ingelheim Investigational Site
Shanghai
1160.26.0782 Boehringer Ingelheim Investigational Site
Shanghai
1160.26.0777 Boehringer Ingelheim Investigational Site
Shenyang
1160.26.0780 Boehringer Ingelheim Investigational Site
Shijiazhuang
Greece13 sites
1160.26.0908 University Hospital of Alexandroupolis
Alexandroupoli
1160.26.0901 General Hospital "Alexandra", Therapeutic Clinic UOA
Athens
1160.26.0906 General Hospital ";Evangelismos"
Athens
1160.26.0907 "Pammakaristos" Hospital of Athens
Athens
1160.26.0915 "Hippokratio" Hospital of Athens
Athens
1160.26.0914 2nd IKA Hospital, Thessaloniki
Kalamaria-Thessaloniki
1160.26.0904 General Hospital of Larissa
Larissa
1160.26.0913 University Hospital of Larissa
Larissa
1160.26.0912 General Hospital of Leivadia
Livadeia
1160.26.0910 General Hospital of Thiva
Thebes
1160.26.0902 General Hospital " Papageorgiou"
Thessaloniki
1160.26.0903 General Hospital of Trikala
Trikala
1160.26.0905 Boehringer Ingelheim Investigational Site
Voula - Athens
Taiwan13 sites
1160.26.1680 Boehringer Ingelheim Investigational Site
Changhua County
1160.26.1683 Boehringer Ingelheim Investigational Site
Hualien City
1160.26.1682 Boehringer Ingelheim Investigational Site
Kaohsiung City
1160.26.1679 China Medical University Hospital
Taichung
1160.26.1681 Boehringer Ingelheim Investigational Site
Tainan
1160.26.1671 Boehringer Ingelheim Investigational Site
Taipei
1160.26.1672 Boehringer Ingelheim Investigational Site
Taipei
1160.26.1673 Boehringer Ingelheim Investigational Site
Taipei
1160.26.1674 Boehringer Ingelheim Investigational Site
Taipei
1160.26.1675 Boehringer Ingelheim Investigational Site
Taipei
1160.26.1676 Boehringer Ingelheim Investigational Site
Taipei
1160.26.1677 Boehringer Ingelheim Investigational Site
Taipei
1160.26.1678 Boehringer Ingelheim Investigational Site
Taoyuan
South Korea12 sites
1160.26.1585 Boehringer Ingelheim Investigational Site
Busan
1160.26.1586 Boehringer Ingelheim Investigational Site
Chungchungnam-Do
1160.26.1584 Boehringer Ingelheim Investigational Site
Daegu
1160.26.1591 Boehringer Ingelheim Investigational Site
Daegu
1160.26.1590 Boehringer Ingelheim Investigational Site
Gwangju
1160.26.1581 Boehringer Ingelheim Investigational Site
Incheon
1160.26.1582 Boehringer Ingelheim Investigational Site
Seoul
1160.26.1583 Boehringer Ingelheim Investigational Site
Seoul
1160.26.1588 Boehringer Ingelheim Investigational Site
Seoul
1160.26.1589 Boehringer Ingelheim Investigational Site
Seoul
1160.26.1592 Boehringer Ingelheim Investigational Site
Seoul
1160.26.1593 Boehringer Ingelheim Investigational Site
Seoul
Denmark11 sites
1160.26.0837 Boehringer Ingelheim Investigational Site
Aalborg
1160.26.0835 Boehringer Ingelheim Investigational Site
Aarhus C
1160.26.0833 Boehringer Ingelheim Investigational Site
Elsinore
1160.26.0838 Boehringer Ingelheim Investigational Site
Frederikssund
1160.26.0834 Boehringer Ingelheim Investigational Site
Herlev
1160.26.0841 Boehringer Ingelheim Investigational Site
Horsens
1160.26.0832 Boehringer Ingelheim Investigational Site
Hvidovre
1160.26.0840 Boehringer Ingelheim Investigational Site
Køge
1160.26.0831 Boehringer Ingelheim Investigational Site
Odense
1160.26.0839 Boehringer Ingelheim Investigational Site
Roskilde
1160.26.0836 Boehringer Ingelheim Investigational Site
Svendborg
Ukraine11 sites
1160.26.1727 Boehringer Ingelheim Investigational Site
Dnyepropetrovsk
1160.26.1724 Boehringer Ingelheim Investigational Site
Kharkiv
1160.26.1725 Boehringer Ingelheim Investigational Site
Kharkiv
1160.26.1726 Boehringer Ingelheim Investigational Site
Kharkiv
1160.26.1721 Boehringer Ingelheim Investigational Site
Kiev
1160.26.1722 Boehringer Ingelheim Investigational Site
Kiev
1160.26.1723 Boehringer Ingelheim Investigational Site
Kiev
1160.26.1728 Boehringer Ingelheim Investigational Site
Kiev
1160.26.1730 Boehringer Ingelheim Investigational Site
Kiev
1160.26.1731 Boehringer Ingelheim Investigational Site
Kiev
1160.26.1729 Boehringer Ingelheim Investigational Site
Lviv
Australia10 sites
1160.26.0509 Boehringer Ingelheim Investigational Site
Ashford, South Australia
1160.26.0504 Boehringer Ingelheim Investigational Site
Box Hill, Victoria
1160.26.0508 Boehringer Ingelheim Investigational Site
Coffs Harbour, New South Wales
1160.26.0501 Boehringer Ingelheim Investigational Site
Geelong, Victoria
1160.26.0510 Boehringer Ingelheim Investigational Site
Gosford, New South Wales
1160.26.0505 Boehringer Ingelheim Investigational Site
Herston, Queensland
1160.26.0507 Boehringer Ingelheim Investigational Site
Launceston, Tasmania
1160.26.0506 Boehringer Ingelheim Investigational Site
Milton, Queensland
1160.26.0502 Boehringer Ingelheim Investigational Site
Parkville, Victoria
1160.26.0503 Boehringer Ingelheim Investigational Site
Prahran, Victoria
Austria10 sites
1160.26.0543 Boehringer Ingelheim Investigational Site
Graz
1160.26.0549 Boehringer Ingelheim Investigational Site
Linz
1160.26.0541 Boehringer Ingelheim Investigational Site
Vienna
1160.26.0542 Boehringer Ingelheim Investigational Site
Vienna
1160.26.0544 Boehringer Ingelheim Investigational Site
Vienna
1160.26.0545 Boehringer Ingelheim Investigational Site
Vienna
1160.26.0547 Boehringer Ingelheim Investigational Site
Vienna
1160.26.0548 Boehringer Ingelheim Investigational Site
Vienna
1160.26.0546 Boehringer Ingelheim Investigational Site
Wels
1160.26.0550 Boehringer Ingelheim Investigational Site
Wiener Neustadt
Czechia10 sites
1160.26.0815 Boehringer Ingelheim Investigational Site
Brno
1160.26.0816 Boehringer Ingelheim Investigational Site
Brno
1160.26.0820 Boehringer Ingelheim Investigational Site
Ostrava
1160.26.0818 Boehringer Ingelheim Investigational Site
Pardubice
1160.26.0814 Boehringer Ingelheim Investigational Site
Plzen-Bory
1160.26.0813 Boehringer Ingelheim Investigational Site
Pragha 9
1160.26.0811 Boehringer Ingelheim Investigational Site
Prague
1160.26.0812 Boehringer Ingelheim Investigational Site
Prague
1160.26.0817 Boehringer Ingelheim Investigational Site
Příbram
1160.26.0819 Boehringer Ingelheim Investigational Site
Ústí nad Orlicí
Hungary10 sites
1160.26.1011 Boehringer Ingelheim Investigational Site
Budapest
1160.26.1012 Boehringer Ingelheim Investigational Site
Budapest
1160.26.1013 Boehringer Ingelheim Investigational Site
Budapest
1160.26.1014 Boehringer Ingelheim Investigational Site
Budapest
1160.26.1015 Boehringer Ingelheim Investigational Site
Budapest
1160.26.1016 Boehringer Ingelheim Investigational Site
Budapest
1160.26.1020 Boehringer Ingelheim Investigational Site
Gyöngyös
1160.26.1017 Boehringer Ingelheim Investigational Site
Komárom
1160.26.1018 Boehringer Ingelheim Investigational Site
Pécs
1160.26.1019 Boehringer Ingelheim Investigational Site
Veszprém
Poland10 sites
1160.26.1436 Boehringer Ingelheim Investigational Site
Gdynia
1160.26.1438 Boehringer Ingelheim Investigational Site
Gdynia
1160.26.1437 Boehringer Ingelheim Investigational Site
Gdynia Redlowo
1160.26.1435 Boehringer Ingelheim Investigational Site
Katowice
1160.26.1439 Boehringer Ingelheim Investigational Site
Krakow
1160.26.1440 Boehringer Ingelheim Investigational Site
Krakow
1160.26.1433 Boehringer Ingelheim Investigational Site
Puławy
1160.26.1431 Boehringer Ingelheim Investigational Site
Warsaw
1160.26.1432 Boehringer Ingelheim Investigational Site
Warsaw
1160.26.1434 Boehringer Ingelheim Investigational Site
Zabrze
Slovakia10 sites
1160.26.1548 Boehringer Ingelheim Investigational Site
Banská Bystrica
1160.26.1541 Boehringer Ingelheim Investigational Site
Bratislava
1160.26.1542 Boehringer Ingelheim Investigational Site
Bratislava
1160.26.1543 Boehringer Ingelheim Investigational Site
Bratislava
1160.26.1544 Boehringer Ingelheim Investigational Site
Bratislava
1160.26.1545 Boehringer Ingelheim Investigational Site
Bratislava
1160.26.1546 Boehringer Ingelheim Investigational Site
Bratislava
1160.26.1549 Boehringer Ingelheim Investigational Site
Košice
1160.26.1550 Boehringer Ingelheim Investigational Site
Košice
1160.26.1547 Boehringer Ingelheim Investigational Site
Žilina
Finland9 sites
1160.26.0856 Boehringer Ingelheim Investigational Site
Espoo
1160.26.0851 Boehringer Ingelheim Investigational Site
HUS
1160.26.0859 Boehringer Ingelheim Investigational Site
Jyväskylä
1160.26.0855 Boehringer Ingelheim Investigational Site
Kuopio
1160.26.0857 Boehringer Ingelheim Investigational Site
Lappeenranta
1160.26.0854 Boehringer Ingelheim Investigational Site
OYS
1160.26.0858 Boehringer Ingelheim Investigational Site
Pori
1160.26.0852 Boehringer Ingelheim Investigational Site
Tampere
1160.26.0853 Boehringer Ingelheim Investigational Site
Turku
Portugal9 sites
1160.26.1456 Boehringer Ingelheim Investigational Site
Amadora
1160.26.1451 Boehringer Ingelheim Investigational Site
Carnaxide
1160.26.1454 Boehringer Ingelheim Investigational Site
Coimbra
1160.26.1459 Boehringer Ingelheim Investigational Site
Coimbra
1160.26.1457 Boehringer Ingelheim Investigational Site
Covilha
1160.26.1453 Boehringer Ingelheim Investigational Site
Lisbon
1160.26.1458 Boehringer Ingelheim Investigational Site
Lisbon
1160.26.1455 Boehringer Ingelheim Investigational Site
Porto
1160.26.1452 Boehringer Ingelheim Investigational Site
Setúbal
South Africa9 sites
1160.26.1562 Boehringer Ingelheim Investigational Site
Bloemfontein
1160.26.1569 Boehringer Ingelheim Investigational Site
Boksburg
1160.26.1561 Boehringer Ingelheim Investigational Site
Cape Town
1160.26.1564 Boehringer Ingelheim Investigational Site
Johannesburg
1160.26.1567 Boehringer Ingelheim Investigational Site
Johannesburg
1160.26.1568 Boehringer Ingelheim Investigational Site
Johannesburg
1160.26.1566 Boehringer Ingelheim Investigational Site
Pretoria
1160.26.1563 Boehringer Ingelheim Investigational Site
Randburg
1160.26.1565 Boehringer Ingelheim Investigational Site
Somerset West
Spain9 sites
1160.26.1601 Boehringer Ingelheim Investigational Site
Barcelona
1160.26.1606 Boehringer Ingelheim Investigational Site
Cadiz
1160.26.1607 Boehringer Ingelheim Investigational Site
Fuenlabrada (Madrid)
1160.26.1604 Boehringer Ingelheim Investigational Site
Leganés, Madrid
1160.26.1603 Boehringer Ingelheim Investigational Site
Madrid
1160.26.1608 Boehringer Ingelheim Investigational Site
Madrid
1160.26.1609 Boehringer Ingelheim Investigational Site
Madrid-San Lorenzo Del Escorial
1160.26.1605 Boehringer Ingelheim Investigational Site
Móstoles (Madrid)
1160.26.1602 Boehringer Ingelheim Investigational Site
Sabadell
Mexico8 sites
1160.26.1318 Hospital General "Dr. Santiago Ramón y Cajal
Durango
1160.26.1311 Hospital Mexico-Americano
Guadalajara
1160.26.1317 hOSPITAL bERNARDETTE
Guadalajara
1160.26.1312 Hospital de Jesus
México
1160.26.1314 Hospital 1o. de Octubre
México
1160.26.1319 Instituto Nacional de Cardiologia
México
1160.26.1313 Hosp. Angeles Centro Medico del Potosi
San Luis Potosí City
1160.26.1322 Hospital Central "Dr. Ignacio Morones Prieto"
San Luis Potosí City
Malaysia7 sites
1160.26.1295 Boehringer Ingelheim Investigational Site
George Town
1160.26.1296 Boehringer Ingelheim Investigational Site
George Town
1160.26.1297 Boehringer Ingelheim Investigational Site
Kajang,Selangor
1160.26.1291 Boehringer Ingelheim Investigational Site
Kuala Lumpur
1160.26.1292 Boehringer Ingelheim Investigational Site
Kuala Lumpur
1160.26.1294 Boehringer Ingelheim Investigational Site
Kuala Lumpur
1160.26.1293 Boehringer Ingelheim Investigational Site
Kuching
Norway7 sites
1160.26.1396 Boehringer Ingelheim Investigational Site
Gjøvik
1160.26.1393 Boehringer Ingelheim Investigational Site
Moss
1160.26.1395 Boehringer Ingelheim Investigational Site
Nordbyhagen
1160.26.1391 Boehringer Ingelheim Investigational Site
Oslo
1160.26.1392 Boehringer Ingelheim Investigational Site
Oslo
1160.26.1397 Boehringer Ingelheim Investigational Site
Oslo
1160.26.1394 Boehringer Ingelheim Investigational Site
Rud
Peru5 sites
1160.26.1415 Hospital Alberto Sabogal
Bella Vista
1160.26.1411 Clinica San Felipe
Jesús María
1160.26.1412 Clínica Anglo Americana
San Isidro
1160.26.1413 Hospital Cayetano Heredia
San Martín de Porres
1160.26.1414 Clínica Vesalio
Urbanización Sto Tomas de San Borja
Philippines5 sites
1160.26.1421 Philippine General Hospital
Manila
1160.26.1422 Manila Doctors Hospital
Manila
1160.26.1424 The Medical City
Pasig
1160.26.1423 Philippine Heart Center
Quezon City
1160.26.1425 St Lukes Medical Center
Quezon City
Thailand5 sites
1160.26.1701 Boehringer Ingelheim Investigational Site
Bangkok
1160.26.1702 Boehringer Ingelheim Investigational Site
Bangkok
1160.26.1703 Boehringer Ingelheim Investigational Site
Chiang Mai
1160.26.1704 Boehringer Ingelheim Investigational Site
Khon Kaen
1160.26.1705 Boehringer Ingelheim Investigational Site
Muang Nakhonratchasima
Hong Kong4 sites
1160.26.1001 Boehringer Ingelheim Investigational Site
Hong Kong
1160.26.1002 Boehringer Ingelheim Investigational Site
Hong Kong
1160.26.1003 Boehringer Ingelheim Investigational Site
Kowloon
1160.26.1004 Boehringer Ingelheim Investigational Site
Kowloon
Switzerland4 sites
1160.26.1652 Boehringer Ingelheim Investigational Site
Basel
1160.26.1655 Boehringer Ingelheim Investigational Site
Bellinzona
1160.26.1651 Boehringer Ingelheim Investigational Site
Bern
1160.26.1654 Boehringer Ingelheim Investigational Site
Lugano
Turkey (Türkiye)4 sites
1160.26.1715 Boehringer Ingelheim Investigational Site
Adana
1160.26.1711 Boehringer Ingelheim Investigational Site
Ankara
1160.26.1713 Gazi Universitesi Tip Fakultesi Kardiyoloji Abd
Ankara
1160.26.1714 Dokuz Eylul Universitesi Tip Fakultesi
Izmir
Colombia3 sites
1160.26.0801 Boehringer Ingelheim Investigational Site
Bogotá
1160.26.0802 Boehringer Ingelheim Investigational Site
Bogotá
1160.26.0803 Boehringer Ingelheim Investigational Site
Bogotá
Romania3 sites
1160.26.1471 Boehringer Ingelheim Investigational Site
Bucharest
1160.26.1472 Boehringer Ingelheim Investigational Site
Bucharest
1160.26.1478 Boehringer Ingelheim Investigational Site
Cluj-Napoca
Singapore2 sites
1160.26.1531 Boehringer Ingelheim Investigational Site
Singapore
1160.26.1532 Boehringer Ingelheim Investigational Site
Singapore
About this study
Official title: Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)
The primary objective of this trial is to demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism.
- Conditions
- Atrial Fibrillation, Stroke
- Being tested
- warfarin, Dabigatran dose 1, Dabigatran dose 2
- Medical subject headings
- Atrial Fibrillation, Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
warfarinDrug
once a day
Dabigatran dose 1Drug
twice daily
Dabigatran dose 2Drug
twice a day
| Study group | Role | What they receive |
|---|---|---|
| Dabigatran dose 2 | Active comparator | twice a day Receives: Drug: Dabigatran dose 2 |
| Warfarin | Active comparator | once a day Receives: Drug: warfarin |
| Dabigatran dose 1 | Active comparator | twice a day Receives: Drug: Dabigatran dose 1 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Yearly Event Rate for Composite Endpoint of Stroke/SEE
Time to first occurrence of stroke or systemic embolic event. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25
Measured: 36 months
Secondary outcomes (5)
Yearly Event Rate for Composite Endpoint of Stroke/SEE/All Cause Death
Time to first occurrence of stroke, SEE or all cause death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25
Measured: 36 months
Yearly Event Rate: Composite of Stroke/SEE/PE/MI/Vascular Death
Time to first occurrence of stroke, systemic embolic event, pulmonary embolism, myocardial infarction including silent myocardial infarction or vascular death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25
Measured: 36 months
Bleeding Events (Major and Minor)
Yearly event rate of bleeds. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25
Major bleeds are adjudicated, whereas minor bleeds are investigator reported.
Measured: 36 months
Clinical Relevant Abnormalities for Intracerebral Hemorrhage and Other Intracranial Hemorrhage (ICH)
Patients with clinical relevant abnormalities for intracerebral hemorrhage, other intracranial hemorrhage (ICH)
Measured: 36 months
Abnormal Liver Function Test
Number of subjects with abnormal liver function test (LFT), i.e., ALT/AST>3xULN and total bilirubin > 2 x ULN
Measured: 36 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Dec 2005 (estimated)
- Study startDec 2005
- Primary completionApr 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (45)Papers the sponsor has linked to this study.
- Other trials for Atrial FibrillationStudies of the same condition, open and under way.
- More trials run by Boehringer IngelheimThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Enrolment
- 18,113 participants (actual)
Sponsor and investigators
- Lead sponsor
- Boehringer Ingelheim
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Population Health Research Institute, Uppsala University
- Investigators
- Boehringer Ingelheim, Study chair, Boehringer Ingelheim
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00262600
- Sponsor's protocol ID
- 1160.26
- Other IDs
- 2005-003894-26, 2005
- Status last verified
- Apr 2014
- First submitted
- 6 Dec 2005
- Last updated
- 17 Apr 2019
- Results posted
- Yes, on ClinicalTrials.gov
Publications
Hijazi Z, Lindback J, Oldgren J, Benz AP, Alexander JH, Connolly SJ, Eikelboom JW, Granger CB, Lopes RD, Siegbahn A, Wallentin L. Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores. Am Heart J. 2023 Jul;261:55-63. doi: 10.1016/j.ahj.2023.03.012. Epub 2023 Mar 27.
PubMed 36990261Reinhardt SW, Desai NR, Tang Y, Jones PG, Ader J, Spertus JA. Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial. PLoS One. 2021 Aug 19;16(8):e0256338. doi: 10.1371/journal.pone.0256338. eCollection 2021.
PubMed 34411158Pol T, Hijazi Z, Lindback J, Oldgren J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Siegbahn A, Wallentin L. Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. Cardiovasc Res. 2022 Jul 20;118(9):2112-2123. doi: 10.1093/cvr/cvab262.
PubMed 34358298Millenaar D, Schumacher H, Brueckmann M, Eikelboom JW, Ezekowitz M, Slawik J, Ewen S, Ukena C, Wallentin L, Connolly S, Yusuf S, Bohm M. Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). Am J Cardiol. 2021 Jun 15;149:27-35. doi: 10.1016/j.amjcard.2021.03.024. Epub 2021 Mar 20.
PubMed 33757788Pol T, Hijazi Z, Lindback J, Alexander JH, Bahit MC, De Caterina R, Eikelboom JW, Ezekowitz MD, Gersh BJ, Granger CB, Hylek EM, Lopes R, Siegbahn A, Wallentin L. Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. Open Heart. 2021 Mar;8(1):e001471. doi: 10.1136/openhrt-2020-001471.
PubMed 33741689Hijazi Z, Wallentin L, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Pol T, Yusuf S, Oldgren J, Siegbahn A. Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. J Am Heart Assoc. 2020 Dec 15;9(24):e018984. doi: 10.1161/JAHA.120.018984. Epub 2020 Dec 9.
PubMed 33292046Wallentin L, Lindback J, Eriksson N, Hijazi Z, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Oldgren J, Siegbahn A. Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. Eur Heart J. 2020 Nov 1;41(41):4037-4046. doi: 10.1093/eurheartj/ehaa697.
PubMed 32984892Bohm M, Brueckmann M, Eikelboom JW, Ezekowitz M, Frassdorf M, Hijazi Z, Hohnloser SH, Mahfoud F, Schmieder RE, Schumacher H, Wallentin L, Yusuf S. Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. Eur Heart J. 2020 Aug 7;41(30):2848-2859. doi: 10.1093/eurheartj/ehaa247.
PubMed 32385506Stam-Slob MC, Connolly SJ, van der Graaf Y, van der Leeuw J, Dorresteijn JAN, Eikelboom JW, Peters RJG, Alings M, Visseren FLJ. Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation. Circulation. 2019 Jun 18;139(25):2846-2856. doi: 10.1161/CIRCULATIONAHA.118.035266. Epub 2019 May 3.
PubMed 31046423Hijazi Z, Verdecchia P, Oldgren J, Andersson U, Reboldi G, Di Pasquale G, Mazzotta G, Angeli F, Eikelboom JW, Ezekowitz MD, Connolly SJ, Yusuf S, Wallentin L. Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE - LY Trial. J Am Heart Assoc. 2019 Jan 22;8(2):e010107. doi: 10.1161/JAHA.118.010107.
PubMed 30651032Kent AP, Brueckmann M, Fraessdorf M, Connolly SJ, Yusuf S, Eikelboom JW, Oldgren J, Reilly PA, Wallentin L, Ezekowitz MD. Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2018 Jul 17;72(3):255-267. doi: 10.1016/j.jacc.2018.04.063. Epub 2018 Jul 9.
PubMed 30012318Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Yusuf S, Wallentin L. Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis. Am Heart J. 2018 Apr;198:169-177. doi: 10.1016/j.ahj.2017.10.015. Epub 2018 Jan 5. No abstract available.
PubMed 29653640Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Yusuf S, Granger CB, Siegbahn A, Wallentin L; ARISTOTLE and RE-LY Investigators. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J. 2018 Feb 7;39(6):477-485. doi: 10.1093/eurheartj/ehx584.
PubMed 29069359Verdecchia P, Reboldi G, Angeli F, Mazzotta G, Lip GYH, Brueckmann M, Kleine E, Wallentin L, Ezekowitz MD, Yusuf S, Connolly SJ, Di Pasquale G. Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study. Europace. 2018 Feb 1;20(2):253-262. doi: 10.1093/europace/eux022.
PubMed 28520924Lauw MN, Eikelboom JW, Coppens M, Wallentin L, Yusuf S, Ezekowitz M, Oldgren J, Nakamya J, Wang J, Connolly SJ. Effects of dabigatran according to age in atrial fibrillation. Heart. 2017 Jul;103(13):1015-1023. doi: 10.1136/heartjnl-2016-310358. Epub 2017 Feb 17.
PubMed 28213368
Study at a glance
From the registry record, last updated by the sponsor on 17 Apr 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)
- ClinicalTrials.gov ID
- NCT00262600
- Acronym / sponsor ID
- 1160.26
- Conditions
- Atrial Fibrillation, Stroke
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 18,113 participants (actual)
- Lead sponsor
- Boehringer IngelheimIndustry (pharma, biotech, devices)
- Collaborators
- Population Health Research Institute, Uppsala University
- Study start
- Dec 2005 (actual)
- Primary completion
- Apr 2009 (actual)
- First posted
- 7 Dec 2005 (estimated)
- Results
- Posted 10 Feb 2011
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this trial is to demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Dabigatran dose 2 | Active comparator | Drug: Dabigatran dose 2twice a day |
| Warfarin | Active comparator | Drug: warfarinonce a day |
| Dabigatran dose 1 | Active comparator | Drug: Dabigatran dose 1twice a day |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (0 listed)
Key exclusion criteria (15 listed)
- Prosthetic heart valves requiring anticoagulation per se, or hemodynamically relevant valve disease that is expected to require surgical intervention during the course of the study
- Severe, disabling stroke within the previous 6 months, or any stroke within the previous 14 days
- Conditions associated with an increased risk of bleeding
- Contraindication to warfarin treatment
- Reversible causes of atrial fibrillation (e.g., cardiac surgery, pulmonary embolism, untreated hyperthyroidism).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| warfarinonce a day | Drug | Warfarin |
| Dabigatran dose 1twice daily | Drug | Dabigatran dose 1 |
| Dabigatran dose 2twice a day | Drug | Dabigatran dose 2 |
Primary outcome
Yearly Event Rate for Composite Endpoint of Stroke/SEE
Time frame: 36 months
Time to first occurrence of stroke or systemic embolic event. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25
5 secondary outcomes
Yearly Event Rate for Composite Endpoint of Stroke/SEE/All Cause Death
Time frame: 36 months
Yearly Event Rate: Composite of Stroke/SEE/PE/MI/Vascular Death
Time frame: 36 months
Bleeding Events (Major and Minor)
Time frame: 36 months
Clinical Relevant Abnormalities for Intracerebral Hemorrhage and Other Intracranial Hemorrhage (ICH)
Time frame: 36 months
Abnormal Liver Function Test
Time frame: 36 months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Apr 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 36990261Hijazi Z, Lindback J, Oldgren J, Benz AP, Alexander JH, Connolly SJ, Eikelboom JW, Granger CB, Lopes RD, Siegbahn A, Wallentin L. Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores. Am Heart J. 2023 Jul;261:55-63. doi: 10.1016/j.ahj.2023.03.012. Epub 2023 Mar 27.
- Derived from this study: PubMed 34411158Reinhardt SW, Desai NR, Tang Y, Jones PG, Ader J, Spertus JA. Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial. PLoS One. 2021 Aug 19;16(8):e0256338. doi: 10.1371/journal.pone.0256338. eCollection 2021.
- Derived from this study: PubMed 34358298Pol T, Hijazi Z, Lindback J, Oldgren J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Siegbahn A, Wallentin L. Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. Cardiovasc Res. 2022 Jul 20;118(9):2112-2123. doi: 10.1093/cvr/cvab262.
- Derived from this study: PubMed 33757788Millenaar D, Schumacher H, Brueckmann M, Eikelboom JW, Ezekowitz M, Slawik J, Ewen S, Ukena C, Wallentin L, Connolly S, Yusuf S, Bohm M. Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). Am J Cardiol. 2021 Jun 15;149:27-35. doi: 10.1016/j.amjcard.2021.03.024. Epub 2021 Mar 20.
- Derived from this study: PubMed 33741689Pol T, Hijazi Z, Lindback J, Alexander JH, Bahit MC, De Caterina R, Eikelboom JW, Ezekowitz MD, Gersh BJ, Granger CB, Hylek EM, Lopes R, Siegbahn A, Wallentin L. Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. Open Heart. 2021 Mar;8(1):e001471. doi: 10.1136/openhrt-2020-001471.
- Derived from this study: PubMed 33292046Hijazi Z, Wallentin L, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Pol T, Yusuf S, Oldgren J, Siegbahn A. Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. J Am Heart Assoc. 2020 Dec 15;9(24):e018984. doi: 10.1161/JAHA.120.018984. Epub 2020 Dec 9.
- Derived from this study: PubMed 32984892Wallentin L, Lindback J, Eriksson N, Hijazi Z, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Oldgren J, Siegbahn A. Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. Eur Heart J. 2020 Nov 1;41(41):4037-4046. doi: 10.1093/eurheartj/ehaa697.
- Derived from this study: PubMed 32385506Bohm M, Brueckmann M, Eikelboom JW, Ezekowitz M, Frassdorf M, Hijazi Z, Hohnloser SH, Mahfoud F, Schmieder RE, Schumacher H, Wallentin L, Yusuf S. Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. Eur Heart J. 2020 Aug 7;41(30):2848-2859. doi: 10.1093/eurheartj/ehaa247.
- Derived from this study: PubMed 31046423Stam-Slob MC, Connolly SJ, van der Graaf Y, van der Leeuw J, Dorresteijn JAN, Eikelboom JW, Peters RJG, Alings M, Visseren FLJ. Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation. Circulation. 2019 Jun 18;139(25):2846-2856. doi: 10.1161/CIRCULATIONAHA.118.035266. Epub 2019 May 3.
- Derived from this study: PubMed 30651032Hijazi Z, Verdecchia P, Oldgren J, Andersson U, Reboldi G, Di Pasquale G, Mazzotta G, Angeli F, Eikelboom JW, Ezekowitz MD, Connolly SJ, Yusuf S, Wallentin L. Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE - LY Trial. J Am Heart Assoc. 2019 Jan 22;8(2):e010107. doi: 10.1161/JAHA.118.010107.
- Derived from this study: PubMed 30012318Kent AP, Brueckmann M, Fraessdorf M, Connolly SJ, Yusuf S, Eikelboom JW, Oldgren J, Reilly PA, Wallentin L, Ezekowitz MD. Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2018 Jul 17;72(3):255-267. doi: 10.1016/j.jacc.2018.04.063. Epub 2018 Jul 9.
- Derived from this study: PubMed 29653640Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Yusuf S, Wallentin L. Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis. Am Heart J. 2018 Apr;198:169-177. doi: 10.1016/j.ahj.2017.10.015. Epub 2018 Jan 5. No abstract available.
Related trials for Atrial Fibrillation
Active, not recruiting
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
Paroxysmal AF
Active, not recruitingObservational study
Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation-Asia
Concomitant Procedures, Atrial Fibrillation
Active, not recruiting
CONVERGE Post-Approval Study (PAS)
Chronic Atrial Fibrillation
Recruiting
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
Ischemic Stroke, Atrial Fibrillation
RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Boehringer Ingelheim study chair
Boehringer Ingelheim
984 sites in 44 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing warfarin, Dabigatran dose 1 and Dabigatran dose 2 in people with Atrial Fibrillation and Stroke, run by Boehringer Ingelheim at 984 sites in 44 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Apr 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 984 sites in United States, Canada, Japan, France, Israel and 39 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 10 Feb 2011). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Yearly Event Rate for Composite Endpoint of Stroke/SEE (time frame: 36 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00262600, which also lists 45 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Apr 2019.